Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 7, Issue 2 , Pages 151-160 , March 2011

Disease progression model for cognitive deterioration from Alzheimer's Disease Neuroimaging Initiative database

References 

  1. Ito K, Ahadieh S, Corrigan B, French J, Fullerton T, Tensfeldt T. Alzheimer's Disease Working Group. A disease progression meta-analysis model in Alzheimer's disease. Alzheimers Dement. 2010;6:39–53
  2. Holford NH, Peace KE. Methodologic aspects of a population pharmacodynamic model for cognitive effects in Alzheimer patients treated with tacrine. Proc Natl Acad Sci USA. 1992;89:11466–11470
  3. Doraiswamy PM, Bieber FM, Kaiser LP, Krishnan KRM, Reuning-Scherer JM, Gulanski BM. The Alzheimer's disease assessment scale: patterns and predictors of baseline cognitive performance in multicenter Alzheimer's disease trials. Neurology. 1997;48:1511–1517
  4. Caro J, Ward A, Ishak K, Migliaccio-Walle K, Getsios D, Papadopoulos G, et al. To what degree does cognitive impairment in Alzheimer's disease predict dependence of patients on caregivers?. BMC Neurol. 2002;2:6
  5. Ashford JW, Schmitt FA. Modeling the time-course of Alzheimer dementia. Curr Psychiatry Rep. 2001;3:20–28
  6. Beal SL, Sheiner LB, Boeckmann AJ, eds. NONMEM Users Guides. Ellicott City, MD: ICON Development Solutions; 1989–2006.
  7. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm. 1992;20:511–528
  8. Maitre PO, Bührer M, Thomson D, Stanski DR. A three-step approach combining Bayesian regression and NONMEM population analysis: application to midazolam. J Pharmacokinet Biopharm. 1991;19:377–384
  9. Ette EI, Ludden TM. Population pharmacokinetic modeling: the importance of informative graphics. Pharm Res. 1995;12:1845–1855
  10. Jack CR, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, Weiner MW, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9:119–128
  11. Holford NHG, Mould DR, Peck C. Disease progression models. In:  Atkinson AJ,  Abernethy DR,  Daniels CE,  Dedrick RL,  Markey SP editor. Principles of Clinical Pharmacology. 2nd ed. New York, NY: Academic Press; 2006;p. 313–322
  12. Mould DR. Development of models of disease progression. In:  Ette EI,  Williams PJ editor. Pharmacometrics: The Science of Quantitative Pharmacology. Hoboken, NJ: John Wiley and Sons; 2007;p. 547–581
  13. Chan PLS, Holford NHG. Drug treatment effects on disease progression. Annu Rev Pharmacol Toxicol. 2001;41:625–659
  14. Mould DR, Denman NG, Duffull S. Using disease progression models as a tool to detect drug effect. Clin Pharmacol Ther. 2007;82:81–86
  15. Atchison TB, Massman PJ, Doody RS. Baseline cognitive function predicts rate of decline in basic-care abilities of individuals with dementia of the Alzheimer's type. Arch Clin Neuropsychol. 2007;22:99–107
  16. Stern RG, Mohs RC, Davidson M, Schmeidler J, Silverman J, Kramer-Ginsberg E, et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. Am J Psychiatry. 1994;151:390–396
  17. Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol. 2004;61:59–66
  18. Cosentino S, Scarmeas N, Helzner E, Glymour MM, Brandt J, Albert M, et al. APOE ε4 allele predicts faster cognitive decline in mild Alzheimer disease Neurology. 2008;70:1842–1849
  19. Small GW, Siddarth P, Burggren AC, Kepe V, Ercoli LM, Miller KJ, et al. Influence of cognitive status, age, and ApoE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia. Arch Gen Psychiatry. 2009;66:81–87
  20. Kryscio RJ, Schmitt FA, Salazar JC, Mendiondo MS, Markesbery WR. Risk factors for transitions from normal to mild cognitive impairment and dementia. Neurology. 2006;66:828–832
  21. Gao S, Hendrie HC, Hall KS, Hui S. The relationships between age, sex, and the incidence of dementia and Alzheimer disease: a meta-analysis. Arch Gen Psychiatry. 1998;55:809–815
  22. Amieva H, Letenner L, Dartigues JF, Rouch-Leroyer I, Sourgen C, D'Alchée-Birée F, et al. Annual rate and predictors of conversion to dementia in subjects presenting mild cognitive impairment criteria defined according to a population-based study. Dement Geriatr Cogn Disord. 2004;18:87–93
  23. Solfrizzi V, Panza F, Colacicco AM, D'Introno A, Capurso C, Torres F, et al. for the Italian Longitudinal Study on Aging Working Group Vascular risk factors, incidence of MCI, and rates of progression to dementia. Neurology. 2004;63:1882–1891
  24. Fleisher AS, Sowell BB, Taylor C, Gamst AC, Petersen RC, Thal LJ for the Alzheimer's Disease Cooperative Study. Clinical predictors of progression to Alzheimer disease in amnestic mild cognitive impairment. Neurology. 2007;68:1588–1595
  25. Fleisher A, Grundman M, Jack CR, Petersen RC, Taylor C, Kim HT, et al. Sex, apolipoprotein E ε4 Status, and hippocampal volume in mild cognitive impairment. Arch Neurol. 2005;62:953–957
  26. Stern Y. Cognitive reserve and Alzheimer disease. Alzheimer Dis Assoc Disord. 2006;20:112–117
  27. Fleisher AS, Sun S, Taylor C, Ward CP, Gamst AC, Petersen RC, et al. Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment. Neurology. 2008;70:191–199

 Alzheimer's Disease Neuroimaging Initiative: Data used in the preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (www.loni.ucla.edu\ADNI). As such, the investigators within the ADNI contributed to the design and implementation of ADNI and/or provided data but did not participate in analysis or writing of this report. ADNI investigators include (complete listing available at www.loni.ucla.edu\ADNI\Collaboration\ADNI_Authorship_list.pdf).

PII: S1552-5260(10)00103-2

doi: 10.1016/j.jalz.2010.03.018

Alzheimer's & Dementia: The Journal of the Alzheimer's Association
Volume 7, Issue 2 , Pages 151-160 , March 2011

Article Tools

* Image Usage & Resolution